Trevia®

Trevia®

Therapeutic Segment: Anti-Diabetic

Generic Name: Sitagliptin phosphate monohydrate

Indication:

In patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control as:

  • Monotherapy
  • Dual Therapy: in combination with metformin HCl or with a sulphonylurea or with a PPARγ agonist (i.e.,
    thiazolidinediones) when the treatment with the single agent alone with diet and exercise does not provide
    adequate glycemic control.
  • Triple Therapy: in combination with metformin HCl and a sulphonylurea or with metformin HCl and a PPARγ (i.e., thiazolidinediones) when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control.
  • Combination with Insulin.

Available as:

Tablets
  • 50MG
  • 100MG